Navigation Links
Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure,as Long-Term Monotherapy and in Combination Therapy

in all treatment groups. No clinically significant changes in glucose or lipids were seen with nebivolol monotherapy during the study. -- "Addition of the Beta-Blocker Nebivolol to Ongoing Therapy in the Management of Mild-to-Moderate Hypertension" by Alan H. Gradman, MD, Chief, Division of Cardiovascular Diseases, The Western Pennsylvania Hospital. [Poster Presentation, P-383: Monday, May 21 from 12 pm to 1 pm (Riverside Hall)] The blood pressure lowering effects and tolerability of nebivolol added to ongoing antihypertensive therapy in patients was evaluated in this 12-week, randomized, double-blind, placebo-controlled study (n=669). Results indicate that, by comparison to placebo, nebivolol incrementally lowers blood pressure in mild to moderate hypertensive patients when added to ongoing antihypertensive therapy consisting of one or two medications from the following classes: ACE inhibitors, ARBs, or diuretics, with an incidence of reported adverse events similar to placebo. -- "Efficacy of the Novel Beta-blocker Nebivolol in Obese and Non-Obese Hypertensive Patients" by James R. Sowers, MD, Professor of Medicine and Physiology, Director Diabetes and Cardiovascular Center, University of Missouri. [Poster Presentation, P-442: Monday, May 21 from 12 pm to 1 pm (Riverside Hall)] The blood pressure lowering effects of nebivolol was compared in non- obese and obese hypertensive patients, a population that typically has a poorer response to treatment and an increased need for multiple medications. The pooled analysis of three randomized, double-blind, placebo-controlled trials of similar design was stratified by patient obesity status (BMI greater than or equal to 30 kg/m2) at baseline (obese, n=878; non-obese, n=1136). Results suggest that once-
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes
Post Your Comments:
(Date:7/2/2015)... 2, 2015 Releases of the ... Aedes aegypti , , reduced the dengue mosquito ... by 95%, well below the modelled threshold ... , The journal PLOS Neglected Tropical Diseases ... genetically engineered mosquitoes. The results showed that in Juazeiro ...
(Date:7/2/2015)... July 2, 2015   EVO Aesthetic Center and ... provider for non-invasive aesthetics in Lakeway, Texas ... treatments with the Astanza Duality laser. The medical spa ... through various medical and laser procedures. Their addition of ... a clear solution to their tattoo regret. ...
(Date:7/2/2015)... DURHAM, N.C. , July 2, 2015 ... of assets related to the ion channel biology platform ... previously been obtained as part of Pfizer,s 2011 acquisition ... Pfizer,s rights to the "Icagen" name and trademark.  XRPro ... comprehensive services for ion channel and transporter drug discovery, ...
Breaking Medicine Technology:Oxitec Mosquito Works to Control Aedes aegypti in Dengue Hotspot 2Oxitec Mosquito Works to Control Aedes aegypti in Dengue Hotspot 3EVO Offers Advanced Laser Tattoo Removal With Astanza Duality In Lakeway, TX 2Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 2Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 3Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 4
... Echo Therapeutics,(OTC Bulletin Board: ECTE) today announced ... Symphony(TM) Transdermal Continuous Glucose Monitoring (tCGM),System in ... Diabetes. Echo,s non-invasive,Symphony tCGM System consists of ... the Prelude(TM) SkinPrep System, which,incorporates leading-edge, needle-free ...
... MITI ), a biopharmaceutical company developing novel, ... autoimmune,diseases, today announced that it will host a ... 2008, at 9:00 am Eastern Time (3:00 pm,Central ... financial,results. Micromet anticipates releasing its financial results at ...
Cached Medicine Technology:Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes 2Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes 3Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes 4Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results 2Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results 3
(Date:7/2/2015)... ... 02, 2015 , ... sweetFrog Enterprises, LLC. is pleased to announce the opening of its newest ... Lone Star State. The premium frozen yogurt chain was listed as #22 on the Inc. ... in the Village at Bachman Lake, is located at:, 3701 W. Northwest Highway, STE 430, ...
(Date:7/2/2015)... ... ... the recent report by JAMA Internal Medicine published on June 22, 2015, ... declared a war on obesity in the United States. , "Obesity is one of ... magnitude of this discovery. For that reason, I am declaring, along with my Health ...
(Date:7/2/2015)... ... 02, 2015 , ... When Walker Parking Consultants specified Kenall ... Minnesota, they knew it would save the university energy and maintenance costs. What ... total energy savings after installation was an impressive 89 percent, which resulted in ...
(Date:7/2/2015)... ... ... full swing, Americans are flocking to Canada’s many lakes to reel in their fair share ... and it’s easy to understand why. From the Pacific Northwest Coast of British Columbia to ... a huge industry, and Americans make up the vast majority of anglers from outside of ...
(Date:7/2/2015)... ... ... LIFX ” was featured on NewsWatch as part of its monthly Tech Report, which ... expert and special reporter for NewsWatch, conducted the review and shared with viewers how ... According to the U.S. Department of Energy, it’s very important to use energy-efficient light ...
Breaking Medicine News(10 mins):Health News:sweetFrog Opens 18th Location in the Lone Star State 2Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 2Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 3Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 4Health News:Kenall’s TekDek™ Helps University Achieve Award-Winning Energy Savings in Parking Structure Lighting Retrofit 2Health News:The Most Versatile Smart Light Bulbs were featured on NewsWatch Television 2
... increased over the past years with more than one-third ... alternative medicine. Alternative or complementary therapies include treatments such ... vitamins. ,Researchers in Boston compared the results ... National Health Interview Survey taken in 2002. Results showed ...
... disorder, where white blood cells attack fatty tissue surrounding nerve ... is twice as common in women as in men . ... with multiple sclerosis. Since MS causes muscle weakness and fatigue, ... of life, researchers designed an exercise program to develop ...
... in as little as two days of physical inactivity, the ... and other related diseases.// ,Researchers conducted a study in ... stayed inactive. When the rats stopped running for two days ... of sugar taken into the muscle in response to insulin ...
... children who have Duchenne muscular dystrophy (DMD) with the oral ... despite the side effects of the drug . Most patients ... teens or early 20s from respiratory failure or heart problems. ... questioned whether its side effects, which can range from weight ...
... carry a gene that produces a higher level of ... for stroke.// ,Researchers reviewed medical literature on homocysteine ... study results were observational in nature. A standard scientific ... looking at data on the link between homocysteine and ...
... disease who follow a heart-healthy diet and weight-loss regimen ... that raise HDL (high-density lipoproteins or "good" cholesterol) levels, ... patients younger than 76 with low HDL and known ... a heart-healthy diet and lost weight. However, results showed ...
Cached Medicine News:
... Measles IgG Enzymelinked Immunosorbent Assays(ELISA) is intended ... IgG antibody to Measles Rubeola) virus in ... used for the determination of immune status. ... to demonstrate seroconversion or a significant rise ...
The DSL-05-01-MEM Measles IgM Enzyme-Linked Immunosorbent Assay (ELISA) kit provides materials for the determination of IgM-class antibodies to Measles virus in human serum. This assay is intended fo...
The DSL-05-10-MEG Measles IgG Enzyme-Linked Immunosorbent Assay (ELISA) kit provides materials for the determination of IgG-class antibodies to Measles Virus in human serum. This assay is intended fo...
... is a glucocorticoid produced by the adrenal ... It is secreted with a circadian periodicity, ... the morning. Cortisol is often elevated in ... stress, AIDS, and in the visceral fat ...
Medicine Products: